Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases.
Bharati ShriyanDeepali PatilMurari GurjarManjunath NookalaAnand PatilSadhana KannanVijay PatilAmit JoshiVanita NoronhaKumar PrabhashVikram GotaPublished in: European journal of clinical pharmacology (2020)
HDG was better tolerated than HDE. CSF disposition of gefitinib was found to be saturable at a higher dose. Based on these findings, the dose of 750 mg OD should be considered for further evaluation in this setting.
Keyphrases
- small cell lung cancer
- brain metastases
- high dose
- epidermal growth factor receptor
- end stage renal disease
- newly diagnosed
- advanced non small cell lung cancer
- ejection fraction
- chronic kidney disease
- prognostic factors
- low dose
- peritoneal dialysis
- cerebrospinal fluid
- patient reported outcomes
- tyrosine kinase
- patient reported